+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 70Years
All Genders
ID06916806

Evaluating the Safety and Pharmacokinetics of AZD5492 in Adults with Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, or Rheumatoid Arthritis

Led by AstraZeneca · Updated on 2026-10-19

72

Participants Needed

38

Research Sites

19 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, pharmacokinetics PK, and pharmacodynamics PD of AZD5492 administered subcutaneously in adults with Systemic Lupus Erythematosus SLE, Idiopathic Inflammatory Myopathies IIM, or Rheumatoid Arthritis RA. This open-label, multi-center Phase I study aims to better understand how the drug behaves in the body and its effects in these autoimmune conditions. The study includes two parts Part 1 involves a single ascending dose SAD of AZD5492 given once to participants with SLE, with up to 5 planned dose levels and potential additional doses based on emerging data. Part 2 uses a step-up dosing SUD design where participants with SLE, IIM, or RA receive either two doses Part 2a or three doses Part 2b spaced 7 days apart to reduce risks of cytokine release syndrome and neurotoxicity. Participants receive the drug as subcutaneous injections on specific days depending on their assigned part. Participants undergo screening for up to 42 days before dosing and are followed for at least 179 days after their last dose, with possible additional follow-ups up to 12 months from study start. During the study, safety and tolerability are closely monitored through adverse event tracking, vital signs, lab tests, and ECGs. Pharmacokinetic parameters and immune response markers are also measured. Those who complete the study may be eligible for re-enrollment and re-treatment under protocol guidelines.

CONDITIONS

Brief Title

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

Research Team

A

AstraZeneca Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here